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Abstract
Introduction The response to paclitaxel varies widely in
metastatic breast cancer. We analyzed data from CALGB 9342,
which tested three doses of paclitaxel in women with advanced
disease, to determine whether response and outcomes differed
according to HER2, hormone receptor, and p53 status.
Methods Among 474 women randomly assigned to paclitaxel at
a dose of 175, 210, or 250 mg/m2, adequate primary tumor
tissue was available from 175. Immunohistochemistry with two
antibodies and fluorescence in situ hybridization were
performed to evaluate HER2 status; p53 status was determined
by immunohistochemistry and sequencing. Hormone receptor
status was obtained from pathology reports.
Results Objective response rate was not associated with HER2
or p53 status. There was a trend toward a shorter median time
to treatment failure among women with HER2-positive tumors
(2.3 versus 4.2 months; P = 0.067). HER2 status was not
related to overall survival (OS). Hormone receptor expression
was not associated with differences in response but was
associated with longer OS (P = 0.003). In contrast, women with
p53 over-expression had significantly shorter OS than those
without p53 over-expression (11.5 versus 14.4 months; P =
0.002). In addition, triple negative tumors were more frequent in
African-American than in Caucasian patients, and were
associated with a significant reduction in OS (8.7 versus 12.9
months; P = 0.008).
Conclusion None of the biomarkers was predictive of treatment
response in women with metastatic breast cancer; however,
survival differed according to hormone receptor and p53 status.
Triple negative tumors were more frequent in African-American
patients and were associated with a shorter survival.
Introduction
The taxanes (paclitaxel and docetaxel) are among the most
active drugs for treatment of breast cancer and are an impor-
tant component of treatment in the neoadjuvant, adjuvant, and
metastatic settings. These drugs act, at least in part, by stabi-
lizing microtubules and inducing G2/M arrest, with subsequent
apoptosis in malignant cells. Paclitaxel, the first taxane that
was developed, has substantial antitumor activity. As a result,Page 1 of 12
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metastatic setting, and it is indicated for the treatment of high-
risk, early-stage breast cancer, in addition to anthracycline-
based therapy [1-8]. However, little is known about the mech-
anisms of sensitivity and resistance to taxanes. Hence, an
important therapeutic goal is to identify molecular predictors of
a response to taxane therapy.
Human epidermal growth factor receptor (HER)2 (ErbB2) is
over-expressed in 25% to 30% of human breast cancers and
is associated with reduced disease-free survival and overall
survival (OS) [9]. Data from Cancer and Leukemia Group B
(CALGB) trial 8869/8541 [10] and National Surgical Adju-
vant Breast and Bowel Project (NSABP) trial B11 [11] indi-
cate an improved response to doxorubicin-containing
regimens in patients whose tumors over-express HER2. Data
on the association between this growth factor and taxane sen-
sitivity are limited and conflicting. In some experimentalsys-
tems, transfection of HER2 leads to paclitaxel resistance by
blocking activation of Cdc2, which is required for paclitaxel-
induced apoptosis [12,13]. HER2 signaling also activates Akt,
providing a survival signal through that pathway [14]. In con-
trast, HER2 activation may increase sensitivity to paclitaxel by
abrogation of the G1/S checkpoint through p27, allowing pro-
gression to G2/M [15].
Clinical studies of HER2 tumor levels in relation to the
response to taxanes have also yielded conflicting results. Sei-
dman and collaborators [16] reported an association between
HER2 over-expression and an improved response to taxanes
in a retrospective analysis of patients with breast cancer who
had been treated in several clinical trials. Other studies have
found no association with treatment response [17,18], resist-
ance to paclitaxel [19], or an improved response in patients
with HER2-positive tumors [20-22]. These differing results
may be due to differences in patient selection, study design
and sample size, and variation in the methods used to deter-
mine HER2 status.
Mutations in the tumor suppressor gene p53 are present in
18% to 25% of primary breast carcinomas [23,24]. In general,
missense mutations lead to nuclear accumulation of p53, but
the mutant protein is not capable of normal p53 function.
Mutations in p53 may increase sensitivity to paclitaxel by abro-
gating the G1 checkpoint, allowing cells to progress to G2/M,
as suggested by in vitro models [25]. In addition, expression
of MAP4 (microtubule-associated protein 4), which occurs
when p53 is transcriptionally silent, stabilizes polymerized
microtubules and increases sensitivity to paclitaxel [26,27].
Alternatively, p53 mutations may lead to taxane resistance,
because mutant p53 cannot upregulate expression of Bax,
which participates in apoptosis [28]. Finally, specific muta-
tions in p53 have been shown to disrupt spindle checkpoint
control, potentially increasing resistance to taxane-induced
damage [29].
Newer approaches to molecular classification of breast can-
cer have identified three distinct subclasses with both biologic
and prognostic significance. These subclasses, defined by
classic biomarkers, are estrogen receptor (ER) and/or proges-
terone receptor (PR) positive tumors, HER2-amplified tumors,
and ER/PR/HER2-negative tumors. The three subtypes have
been reproducibly identified by gene expression profiling in
multiple breast cancer cohorts and exhibit consistent prognos-
tic significance [30-34]. In addition, it was recently reported
that African-American women are more likely to have the 'triple
negative' breast cancer phenotype [35,36]. These tumors lack
expression of ER, PR, and HER2; they express basal keratins
and myoepithelial markers; and they are associated with worse
outcome in early-stage breast cancer [34,37].
In CALGB 9342, women with advanced breast cancer were
randomly assigned to paclitaxel, given alone as first-line or sec-
ond-line chemotherapy, at one of three dose levels [8]. We
conducted a biomarker companion study to determine
whether HER2 status (measured by immunohistochemistry
[IHC] and fluorescent in situ hybridization [FISH]), hormone
receptor status, p53 status (measured by IHC and sequenc-
ing), or a combination of these markers predicted clinical out-
comes in this cohort of patients with metastatic breast cancer.
We also determined the frequency of molecular markers in
African-American women and examined whether race influ-
enced outcomes.
Materials and methods
Trial design
Women with histologically documented advanced breast can-
cer (stage IV or inoperable) who had measurable disease, an
Eastern Cooperative Oncology Group performance status of
0, 1, or 2, a life expectancy of at least 12 weeks, and adequate
end-organ function were eligible for enrollment in CALGB
9342. Patients were required not to have received more than
one prior chemotherapy regimen for metastatic disease, and
concurrent hormonal therapy was not permitted. Women were
randomly assigned to receive paclitaxel at one of three doses
– 175 mg/m2, 210 mg/m2, or 250 mg/m2 – administered as a
3-hour infusion every 3 weeks. Standard staging studies were
repeated after every three cycles. Patients were treated until
progression of disease or toxicity required discontinuation of
paclitaxel.
The study was approved by the institutional review boards of
the participating centers, and all patients provided written
informed consent. Of the 474 women who were enrolled, 469
received at least one cycle of paclitaxel as specified by the
study protocol. A detailed description of the study design and
results has previously been published [8].
Objective response criteria
Response to paclitaxel was assessed radiographically every
three cycles. A response was documented if radiographicPage 2 of 12
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pearance of all lesions, or a partial response, defined as at
least a 50% reduction in the sum of the products of bidimen-
sional measurements for all lesions, with improvement or no
change in any nonmeasurable lesions. In the case of patients
for whom response data were not available, those who were
known to have had excessive toxicity or to have died early were
included in the analysis as nonresponders. Patients for whom
no follow-up information was available were excluded from the
analysis.
Hormone receptor status
Information on hormone receptor status was obtained from
pathology reports.
Block collection and evaluation
Paraffin-embedded tumor tissue blocks were available from
201 (42%) of the 474 patients. For the other 273 patients,
blocks were not available because they had been discarded as
per institutional policy, because the resources for block collec-
tion were inadequate, or because the patient had died and the
local institutional review board would not allow release of the
tissue.
All samples were reviewed by a designated pathologist (IB).
Sections stained with hematoxylin and eosin were evaluated
for histologic grade and nuclear grade. Corresponding blocks
that passed quality assurance were sent to the appropriate
laboratory for analyses of HER2 and p53 status. Technicians
were blinded as to outcome, race, and all other aspects of the
clinical data. Because conflicting findings in previous studies
of HER2 status and the response to paclitaxel may have been
due to assay differences, three methods of measuring HER2
were used, and the level of agreement among them was
determined.
Immunohistochemistry studies of HER2 and p53
Analyses were conducted on formalin-fixed, paraffin-embed-
ded specimens of tissue from the primary breast tumor, a
lymph node metastasis, or a distant metastasis. Only one sam-
ple per patient was selected for the final analysis, with the
sample from the primary site being used when available (90%
of patients).
Immunostaining for HER2/neu expression was performed with
the use of monoclonal antibody CB11 (Biogenex, San Ramon,
CA, USA) and the Vector Avidin Biotin Complex (ABC) kit
(Vector Laboratories, Burlingame, CA, USA), in accordance
with the manufacturer's guidelines. After development with
SG chromogen (Vector Laboratories), sections were counter-
stained with nuclear fast red. A positive result was defined as
staining of moderate to strong intensity in at least 10% of the
invasive carcinoma cells.
HER2 immunostaining was also performed with the Her-
cepTest (Dako Corp., Carpinteria, CA, USA), in accordance
with the manufacturer's guidelines. A positive result was
defined as a staining score of 3+, with complete membrane
staining of more than 10% of tumor cells.
Expression of p53 was evaluated with the use of the D07 anti-
body (Oncogene Science, Cambridge, MA, USA) and the
Vector ABC kit, in accordance with the manufacturer's guide-
lines. After incubation overnight with the D07 antibody, sec-
tions were developed with diaminobenzidine as the
chromogen and counter-stained with hematoxylin. A positive
result was defined as distinct nuclear staining in at least 10%
of the invasive carcinoma cells.
Fluorescence in situ hybridization analysis of HER2
HER2 gene amplification was performed with the use of the
Vysis PathVysion kit (Vysis, Inc., Downers Grove, IL, USA), in
accordance with the manufacturer's guidelines. Specimens
were considered amplified if the ratio of HER2 to CEP17 sig-
nal was greater than or equal to 2.0.
p53 Mutation analysis
DNA was extracted from four 4 μmol/l formalin-fixed, paraffin-
embedded tissue sections with macrodissection of epithelial
elements away from stromal tissue (TN, AM, LH). After solubi-
lization with xylene and overnight digestion of the tissue in pro-
teinase K, DNA was isolated with the use of the Purgene kit
(Gentra Systems, Minneapolis, MN, USA). After amplification,
polymerase chain reaction products were purified, and termi-
nator-based sequencing kits with Big Dye technology (Perkin-
Elmer, Wellesley, MA, USA) were used to determine the
sequence of each of the p53 coding exons (exons 2 through
10). The presence of mutations was ascertained using the
Sequencher program (Gene Codes Corp., Ann Arbor, MI,
USA). Mutations were confirmed by repeat sequencing of all
exons. Identified mutations were compared with the p53 muta-
tion database maintained at Hôpital Necker-Enfants Malades
in Paris, France [38].
Statistical methods
Each specimen was assigned a unique laboratory identifica-
tion number. Laboratory investigators were unaware of patient
identity and outcome data. Results were analyzed by the sta-
tistical center at CALGB (GB and DB).
The initial target for accrual was 332 patients (70% of the
overall study population), with a goal being to evaluate the
dose response to paclitaxel, dichotomized by biomarker sta-
tus. Because the response rate was equivalent among the
three groups in the overall study, and because the number of
tissue blocks collected was less than anticipated, the three
dose levels were combined for the current analysis. A dichot-
omous variable was generated for each biomarker (positive or
negative).Page 3 of 12
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agreement between HER2 assay methods. We used a test of
proportions to compare patient characteristics that were
dichotomous. For patient characteristics collected as continu-
ous variables, we compared median values, using the Wil-
coxon rank-sum test. Response rates were compared on the
basis of categorization of clinical variables and HER2 and p53
status, with the use of a test of proportions. Time to treatment
failure (TTF) was measured as the time from study entry to the
first locoregional recurrence, first distant metastasis, or death
due to any cause; data were censored for patients without
events at the last follow-up date. OS was measured as the
time from study entry to death, with data censored at the last
follow up. Time to event and Kaplan-Meier curves were com-
pared using the log-rank test. Hazard ratios and their 95%
confidence intervals (CIs) were calculated for multivariate Cox
proportional hazards modeling. The significance of variables in
multivariate Cox models was determined using the χ2 test. All
statistical tests were two sided.
Results
Baseline and follow-up characteristics of the patients
Paraffin-embedded tissue blocks were available for 201 of the
474 patients enrolled in CALGB 9342. Blocks from 175
patients passed quality control. A total of 165 patients with at
least one biomarker measurement are included in this com-
panion study. The median follow-up time was 8.3 years among
patients with at least one biomarker measurement and 8.5
years for the remaining study population (Table 1). The only
significant difference between the two groups was the shorter
median disease-free interval among patients with biomarker
measurements (19 versus 31 months; P = 0.0003). Because
blocks are often discarded after 10 years, patients with availa-
ble blocks would, by definition, have a shorter interval between
diagnosis and metastasis.
Hormone receptor, HER2, and p53 status
Information on hormone receptor status was available for 148
of the 201 patients from whom tissue blocks were collected.
Of these 148 patients, 74 (50%) had tumors that were
reported to be hormone receptor positive.
The CB11 assay of HER2 was informative in 162 cases, the
HercepTest in 158 cases, and FISH in 152 cases. The results
of these assays are summarized in Table 2 and their sensitivity
and specificity in Table 3.
The D07 antibody assay for p53 protein was informative in
150 cases; 57 tumors (38%) exhibited evidence of p53 pro-
tein over-expression by this method.
p53 Mutations
Sequencing of exons 4 to 11 of the p53 gene was informative
in the 152 cases in which we were able to extract adequate
DNA from the tumor specimen; 51 mutations were found in 44
patients (29%). Tumors from six patients contained more than
one mutation in p53; in the remainder a single mutation was
identified. Approximately half were missense mutations, and
31% were categorized as 'other' (in intron sequences). The
remaining mutations were classified as splice mutations (9%)
or as silent, nonsense, or frameshift mutations (4% each). The
largest proportion of mutations was found in either intron 7
(27%) or exon 5 (22%). Mutations in exons 7 and exon 8
accounted for 12% and 18% of the identified mutations,
respectively. Mutations in exons 4 and 10 were rare, and there
were no mutations in exon 9. Only two tumors were found to
Table 1
Patient characteristics
Characteristic Patients with biomarker
measurements
Patients without biomarker
measurements
P value
ER positive and/or PR positive (n [%]) 85 (58%) 159 (62%) 0.45a
Prior adjuvant chemotherapy (n [%]) 98 (60%) 161 (56%) 0.31a
Objective response (complete or partial; n [%]) 38 (24%) 66 (23%) 0.88a
Median age (years) 54.9 57.2 0.25b
Median follow up (years) 8.3 8.5 0.77b
Median number of metastatic sites (n) 1 1 0.14b
Median disease-free survival (months) 19 31 0.0003b
Median time to progression (months) 4.1 4.3 0.62c
Median overall survival (months) 12.6 12.3 0.81c
Note that data regarding hormone receptor status and prior adjuvant chemotherapy were not available for all patients enrolled in CALGB 9342, 
and the total number is therefore less than 469 for some of the comparisons. aP value is based on the test for comparing two proportions. bP value 
is based on the Wilcoxon rank-sum test for comparing median values. cP value is based on a comparison of Kaplan-Meier curves with the log-rank 
test.Page 4 of 12
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associated with defects in spindle checkpoint control.
Because not all mutations in p53 lead to IHC evidence of p53
over-expression, we assessed the sensitivity and specificity of
IHC for detecting p53 mutations that had been identified by
sequencing. We found that IHC had a sensitivity of 63% and
a specificity of 73%. Because previous studies have shown
that over-expression of p53 is highly correlated with missense
mutations [39], we evaluated the level of agreement between
IHC evidence of p53 over-expression and the presence of a
missense mutation in p53. IHC detected the majority of mis-
sense mutations identified by sequence analysis, with a sensi-
tivity of 90%. However, the specificity was 72%, reflecting the
fact that not all mutations detected by sequencing were
detected by IHC.
Treatment response
The rate of response to paclitaxel did not differ significantly on
the basis of HER2 or p53 status (Table 4). The response rate
was 23% among women with HER2-positive tumors and 24%
among those with HER2-negative tumors (P = 0.96); the
respective response rates for tumors with and for those with-
out p53 over-expression were 23% and 21% (P = 0.79).
Lower response rates were observed in patients aged 50
years or less (14% versus 29%) and a HER2 score of 0 to 1+
(18% versus 35%); however, only age was significantly asso-
ciated with TTF (P = 0.045) after adjustment for ER/PR status
and HER2 status (Table 5).
Outcomes
There was no meaningful difference in TTF between tumors
with and without p53 over-expression (median time: 4.0
months versus 4.4 months; P = 0.061); however, OS was sig-
nificantly reduced in this group of patients (11.5 months ver-
sus 14.4 months; P = 0.002; Figure 1). There was a trend
toward a shorter TTF among patients who were HER2 positive
than among those who were HER negative (2.3 months versus
4.2 months; P = 0.067), but HER2 status was not associated
with statistically significant differences in OS (Table 6).
Although TTF did not differ by ER status (P = 0.13) in the
biomarker subset, OS was significantly better in this group of
ER-positive tumors (P = 0.003). This observation was also
true of ER status in the entire cohort of patients from CALGB
9342, in which TTF did not differ by ER status (P = 0.27),
whereas ER positivity was associated with more favorable OS
(P = 0.0003).
To determine whether particular p53 mutations predicted a
worse outcome, we grouped missense mutations into nono-
verlapping categories, according to the methodology of Alsner
and coworkers [24]. However, the number of patients in each
subgroup was too small to make meaningful comparisons
(nine with mutations in direct DNA contact or zinc binding
residues, 10 with mutations in conserved domains, and 18
with mutations outside conserved domains).
Table 2
Results of HER2 Immunohistochemistry and FISH
Assay Patients (n [%])
HER2 CB11 score
Negative 130 (80%)
Positive 32 (20%)
Total 162 (100%)
HER2 HercepTest score
0 63 (40%)
1 45 (28%)
2 17 (11%)
3 33 (21%)
Total 158 (100%)
HER2 FISH
HER2/CEP17 ratio <2.0 113 (74%)
HER2/CEP17 ratio ≥2.0 39 (26%)
Total 152 (100%)
FISH, fluorescent in situ hybridization.
Table 3
Agreement among methods for measuring HER2
Method Cohen's kappa Sensitivity Specificity
FISH versus CB11 83.0% (SE 5.3%) 97% 93%
HercepTest versus FISH
(0–1 versus 2–3) versus FISH 72.0% (SE 6.2%) 92% 87%
(0–2 versus 3) versus FISH 79.2% (SE 6.0%) 78% 97%
HercepTest versus CB11
(0–1 versus 2–3) versus CB11 70.0% (SE 6.3%) 100% 85%
(0–2 versus 3) versus CB11 84.2% (SE 5.4%) 90% 96%
FISH, fluorescent in situ hybridization; SE, standard error for Cohen's kappa.Page 5 of 12
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Objective response rates by clinical characteristics, HER2 status, and p53 status
Variable Number of patientsa Response rate (%) P valueb
Age 0.045
>50 years 108 29
≤50 years 50 14
Performance status 0.81
0 77 23
1 or 2 80 25
ER 0.056
Positive 70 17
Negative 71 31
PR 0.51
Positive 64 22
Negative 71 27
ER/PR 0.22
At least 1 positive 81 20
Both negative 59 29
Number of metastatic sites 0.50
0–2 139 25
>2 17 18
Disease-free interval 0.10
≤2 years 101 20
>2 years 57 32
Prior adjuvant chemotherapy 0.83
Yes 94 24
No 61 23
HER2 CBll 0.96
Positive 30 23
Negative 126 24
HER2 FISH 0.70
Positive 37 22
Negative 109 25
HER2 HercepTest 0.026
Positive: 2–3 46 35
Negative: 0–1 105 18
HER2 HercepTest 0.98
Positive: 3 30 23
Negative: 0–2 121 23
p53 IHC 0.79
Positive 56 23
Negative 89 21
p53 Mutation 0.55
Present 42 21
Absent 103 26
aNot all patients could be evaluated for a response, and those who could not be evaluated have been excluded. bP values are for comparisons of 
the proportion of patients with a response to paclitaxel in each group. ER, estrogen receptor; FISH, fluorescent in situ hybridization; IHC, 
immunohistochemistry; PR, progesterone receptor.Page 6 of 12
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Of the 136 patients in this study for whom complete biomarker
data were available, 44 had tumors that were found to carry
the triple-negative phenotype (ER negative, PR negative, and
HER2 negative). There was a higher proportion of triple-nega-
tive tumors with over-expression of p53 on IHC, but this result
did not reach statistical significance (53% versus 36%; P =
0.088). We conducted an exploratory analysis to determine
the objective response rate, TTF, and OS in patients with the
triple-negative phenotype. We found that neither the response
rate nor TTF differed in the triple-negative subgroup as com-
pared with all other patients (response rate: 26% versus 23%,
P = 0.70; TTF: 2.8 months versus 4.5 months, P = 0.092).
However, the triple-negative phenotype was associated with a
significant decrement in OS (8.6 months versus 12.8 months;
P = 0.008; Figure 2). The results were similar when FISH was
used to determine HER2 negativity in this subgroup (8.8
months versus 11.7 months; P = 0.038).
Outcomes and biomarkers according to race
A total of 105 (22%) of the participants in CALGB 9342 iden-
tified themselves as African-American. An exploratory analysis
showed that the response rate and TTF were similar in African-
American women and Caucasian women. However, the
median OS was significantly shorter among African-American
women (10.1 months versus 13.1 months; P = 0.0005); the
difference persisted in a multivariate analysis (hazard ratio
1.44, 95% CI 1.13 to 1.84).
The proportion of African-American women in the subset of
patients with biomarker data (20.6%; n = 34) was similar to
the proportion in the overall group. Tumors were HER2 posi-
tive, according to the CB11 assay, in 9% of African-American
women, as compared with 22% of Caucasian women (P =
0.08). The percentage of African-American women presenting
with tumors that were negative for ER, PR, and HER2 expres-
sion was more than twice that of Caucasian women (47%
versus 21%; P = 0.003; Table 7). Both TTF and OS were sig-
nificantly worse among African-American women than among
Caucasian women (P = 0.038 and P = 0.045, respectively), a
difference that persisted in a multivariate analysis (hazard ratio
1.44, 95% CI 1.13 to 1.84). However, when evaluating dis-
ease-free survival and OS in triple-negative tumors, survival did
not differ by race, suggesting that the negative outcome of
African-American women in this cohort is attributable to the
greater proportion of triple-negative tumors and not other
race-related variables (Figure 2). Of note, there were no signif-
icant differences between the proportions of African-American
Table 5
Cox proportional hazards univariate modeling for time to treatment failure and overall survival
Variable Time to treatment failure Overall survival
Hazard ratio (95% CI) P valuea Hazard ratio (95% CI) P valuea
Univariate modeling
Age >50 years 0.59 (0.42–0.83) 0.0051 0.64 (0.46–0.89) 0.041
Performance status: 0 versus 1 or 2 1.30 (0.95–1.78) 0.11 1.41 (1.03–1.94) 0.031
ER positive 0.78 (0.56–1.08) 0.13 0.61 (0.43–0.84) 0.0029
PR positive 0.72 (0.51–1.00) 0.53 0.71 (0.51–1.00) 0.049
ER/PR positive 0.72 (0.51–1.00) 0.53 0.62 (0.44–0.86) 0.0048
Number of metastatic sites: 0 to 2 versus 3+ 1.72 (1.03–2.88) 0.37 1.10 (0.66–1.82) 0.72
Disease-free interval: ≤2 years versus >2 years 0.72 (0.52–1.00) 0.49 0.81 (0.59–1.12) 0.20
Prior adjuvant chemotherapy 0.87 (0.63–1.20) 0.39 0.93 (0.68–1.29) 0.67
HER2 positive by CB11 1.44 (0.97–2.15) 0.68 1.34 (0.91–1.99) 0.41
HER2 positive by FISH 1.22 (0.85–1.76) 0.29 1.24 (0.86–1.79) 0.25
HER2 by HercepTest: 0–1 versus 2–3 1.02 (0.73–1.43) 0.90 1.04 (0.74–1.46) 0.83
HER2 by HercepTest: 0–2 versus 3 1.34 (0.91–1.98) 0.14 1.11 (0.76–1.64) 0.59
Multivariate modeling
Age >50 years 0.99 (0.97–1.00) 0.045 0.99 (0.97–1.00) 0.10
ER/PR positive 1.28 (0.89–1.82) 0.18 1.55 (1.08–2.22) 0.017
HER2 negative on HercepTest: 0–1 versus 2–3 0.97 (0.68–1.40) 0.88 0.93 (0.65–1.35) 0.71
aP values were calculated using the log-rank test. CI, confidence interval; ER, estrogen receptor; FISH, fluorescence in situ hybridization; PR, 
progesterone receptor.Page 7 of 12
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assessed by IHC (41% and 38%, respectively; P = 0.78) or
by sequencing (32% and 26%, P = 0.48).
Discussion
We evaluated the relationship among tumor biomarkers, treat-
ment response, and outcomes in a subset of patients with
available tumor blocks who were enrolled in a large, prospec-
tive, randomized trial of single-agent paclitaxel given as first-
line or second-line therapy for metastatic breast cancer.
Neither HER2 status nor p53 status significantly affected the
treatment response or TTF when HER2 over-expression was
scored as 3+ on the HercepTest or FISH positive. Although
p53 status and ER status were not predictive of a benefit from
therapy, measured by response or TTF, they were both impor-
tant variables in determining OS in this cohort. Thus, it appears
that p53 and ER status behaved as prognostic factors in this
study, but they did not add predictive value within the context
of response to paclitaxel. Although not surprising, this obser-
vation underlines the importance of separating response to
therapy from the underlying biology, a distinction first made by
McShane and coworkers [40]. In addition, our study provides
support for the use of classification systems that include ER,
PR, and HER2 status, because the outcomes according to
these biomarkers in our cohort are consistent with published
data [30,34]. Furthermore, racial differences in the pattern of
tumor subtypes are also seen, a finding that translates into dif-
ferences in survival, even in the metastatic setting.
Other studies have examined response to taxanes based on
HER2 status. Seidman and coworkers [16] reported a higher
rate of response to paclitaxel in patients with HER2-positive
tumors; however, this association was seen only when HER2
status was assessed with the use of the 4D5 antibody, and not
when a rabbit polyclonal antibody (pAb-1) was used to deter-
mine HER2 status. The authors reported a low level of agree-
ment between the results of the 4D5 assay and an assay with
pAb-1. The monoclonal antibody CB11 and the polyclonal
antibody used in the HercepTest are known to target different
epitopes of HER2 and appear to vary in the specificity of their
results. Therefore, in the present study we evaluated the cor-
relation among three methods of measuring HER2 status that
have been approved by the US Food and Drug Administration.
We found that the results of the CB11 assay, the HercepTest,
and FISH were reasonably concordant, with the highest level
of agreement between the CB11 assay and FISH.
No association was seen between the rate of response to
paclitaxel and HER2 status as assessed by any method. In
contrast to our findings, Konecny and coworkers [21] reported
a statistically significant increase in response rate to epirubicin
and paclitaxel, but not to epirubicin and cyclophosphamide, in
women with HER2-positive tumors, as assessed by FISH. One
possible explanation for these conflicting results is that the
patient populations were not entirely comparable, because all
patients in the study reported by Konecny and coworkers
received treatment as first-line therapy, whereas in CALGB
9342 paclitaxel was given as either first-line or second-line
therapy for metastatic disease. In addition, the treatment regi-
mens were not entirely comparable. There may be an advan-
tage to combining an anthracycline with a taxane in women
with HER2-positive tumors; if so, epirubicin plus paclitaxel may
be a particularly effective regimen against HER2-positive
breast cancer, whereas HER2 status may not influence the
likelihood of a response to paclitaxel given alone. Furthermore,
FISH techniques differed between these studies and might
have influenced the findings. Finally, our sample was relatively
Figure 1
Time to treatment failure and overall survival according to p53 status, as assess d by immunochemistry
as assessed by immunochemistry. (a) Time to treatment failure and (b) 
overall survival. Patients were classified as p53 positive (solid line) or 
p53 negative (dashed line) as determined by immunochemistry with 
D07 antibody. A positive case is defined as ≥10% positive, localization 
of nuclear or nuclear and cytoplasmic, and intensity of stain weak, mod-
erate, or intense. IHC, immunohistochemistry.Page 8 of 12
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HER2-positive tumors and those with HER2-negative tumors
suggests that a substantial difference in response rates would
be unlikely in a larger sample.
Our data showed that hormone receptor status is important as
a prognostic factor in this study but was not predictive of
clinical response or TTF after paclitaxel therapy. Conflicting
data have been reported regarding the role of ER in predicting
benefit from taxane therapy. In CALGB 9344, a subgroup
analysis demonstrated that the addition of paclitaxel in the
adjuvant setting was more beneficial in women with ER/PR-
negative tumors than in those with ER/PR-positive tumors [1].
This observation is supported by a combined analysis con-
ducted by Henderson and coworkers [41], which demon-
strated a strong relationship between ER/PR negativity and a
benefit from chemotherapy. However, the results of the
NSABP B-28 trial [2] and the Breast Cancer International
Research Group (BCIRG) 001 trial [42] do not support this
finding. Our study suggests that differences in survival as a
Table 6
HER2 status and median overall survival
Method for ascertaining HER2 HER2 positive HER2 negative Log-rank P value
CB11 11.3 months 13.1 months 0.14
FISH 10.9 months 13.1 months 0.26
HercepTest: 2–3 versus 0–1 11.5 months 13.2 months 0.84
FISH, fluorescence in situ hybridization.
Figure 2
Time to treatment failure and overall survival for triple-negative subgroup, by race. Time to treatment failure: (a) not triple negative and (b) triple neg-
ative. Overall survival: (c) not triple negative and (d) triple negative. Patients were classified by race (African-American [dashed line] or Caucasian 
[solid line]) and divided into subsets based on triple-negative status. Exploratory analysis to investigate the interaction of triple negative status and 
race.Page 9 of 12
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analyses of trials in the metastatic setting, even among patient
populations that have previously received hormonal therapy.
We further evaluated the relationship among p53 status, race,
and outcomes in this cohort. We found that the presence of
p53 over-expression, as detected by IHC, was not predictive
of the response to paclitaxel but was associated with signifi-
cantly diminished OS. There are two possible explanations for
these findings. First, mutations in p53 may lead to genomic
instability in vitro, with resistant clones arising more rapidly in
these tumors, even though the initial response to therapy is the
same as that in tumors without p53 mutations. It is also possi-
ble that other tumor features that predict a worse prognosis
are associated with p53 mutations and influence survival with-
out affecting response to therapy.
In this study p53 over-expression, as determined by IHC, was
associated with decreased survival, but p53 mutations identi-
fied by sequence analysis were not. Explanations include the
possibility that certain p53 mutations have little effect on the
tumor phenotype, whereas the presence of p53 stabilization is
a surrogate for a mutation with a functional effect. The study
was not sufficiently powered to allow for a rigorous examina-
tion of the interaction between mutation type and clinical out-
come. Furthermore, previously described p53 mutations were
not detected in approximately one-quarter of cases in which
the IHC assay for p53 was positive. We used stringent criteria
for the classification of mutations; only those included in the
p53 mutation database maintained at Hôpital Necker-Enfants
Malades were considered true mutations. Furthermore, it is
possible that some of the mutations identified by sequencing
but not included in the database represent true functional
mutations.
Large, population-based studies have documented racial dis-
parities in breast cancer outcomes [43]. As demonstrated by
Polite and coworkers [44], self-reported African-American
women from CALGB 9342 had decreased survival as com-
pared with their Caucasian counterparts, even with adjust-
ment for other factors. In this biomarker substudy, we
observed the association between African-American race and
worse outcome. A potential explanation for these findings is
the observation that these patients were twice as likely to have
tumors that were negative for ER, PR and HER2, and triple-
negative status was itself associated with significantly poorer
OS. Because we did not collect data on post-study treatment,
we cannot rule out differences in care received after the study
as a cause of the observed disparity. However, our results
extend the observations of Olopade [36] and Carey [35] and
their groups, who reported that basal-like tumors are more
common in women of African ancestry. Because the basal-like
phenotype has been associated with a poor prognosis, our
findings suggest that differences in the biologic features of
tumors may explain the decreased survival of African-American
women in our study. To our knowledge, this is the first study to
demonstrate that the association between a poor prognosis
and the triple-negative phenotype persists in women with met-
astatic breast cancer.
The study had several limitations. First, we were able to obtain
adequate tumor blocks from only approximately one-third of
patients enrolled in CALGB 9342. As a result, the power to
detect all but substantial differences in outcomes based on
biomarkers was limited. Second, we cannot rule out the possi-
bility that the dose-response curve for paclitaxel differs
according to HER2 status; unfortunately, our sample was not
large enough to carry out such an analysis. Third, 90% of the
biomarker assays were performed on blocks from primary
tumors (and 10% on blocks from synchronous lymph-node
metastases), on the assumption that HER2 status is stable
over time regardless of disease progression or interim thera-
pies. A recent abstract has questioned this assumption [45],
reporting discordance in HER2 expression between primary
and metastatic sites in eight (14%) of 58 patients. Finally, pat-
terns of gene expression may ultimately be more useful than
single gene markers in predicting the response to therapy [46-
48].
Conclusion
Molecular subtyping has become commonplace in breast can-
cer, but the implications of molecular markers in patients with
metastatic disease remains unclear. This study suggests that
tumor response is not dictated by p53, HER2 or ER status, but
that these tumor features impact on tumor regrowth and death
in patients with metastatic breast cancer. In addition, the
Table 7
Race according to biomarkers
Biomarker Race P valuea
Caucasian African-American
ER positive 58/109 (53%) 13/32 (41%) 0.21
HER2 positive 27/121 (22%) 3/34 (9%) 0.08
Triple negative 26/121 (21%) 16/34 (47%) 0.003
aP values were obtained using a test of proportions. ER, estrogen receptor.Page 10 of 12
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phenotype in African-American patients was confirmed. Fur-
thermore, this study is the first to point out that the negative
prognosis of triple-negative tumors continues beyond the
diagnosis of metastasis, but it does not seem to relate to tumor
response, at least to paclitaxel. These observations further
point out the importance of tumor biology in behavior of breast
cancer in the clinical setting.
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